11442 Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 

other than their time. Based on a 

maximum of 12 EIs per year and 100 

participants each, the total estimated 

annualized burden hours are 600. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden 

per response 

(in hours) 

Exposure Investigation Participants ................ Chemical Exposure Questions ....................... 1,200 1 30/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–04189 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–70–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–22–0010; Docket No. CDC–2022– 

0030] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled Birth Defects Study To Evaluate 

Pregnancy exposureS (BD–STEPS). Data 

from BD–STEPS will play an important 

part in the decision-making process that 

determines federal research agendas, 

birth defect prevention activities, and 

the direction of funding programs such 

as cooperative agreements. 

DATES: CDC must receive written 

comments on or before May 2, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0030 by either of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Birth Defects Study to Evaluate 

Pregnancy exposureS (BD–STEPS) 

(OMB Control No. 0920–0010, Exp. 2/ 

28/2023)—Extension—National Center 

on Birth Defects and Developmental 

Disabilities (NCBDDD), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

Birth defects are associated with 

substantial morbidity and mortality in 

the United States. About one in every 33 

babies is born with a birth defect. Birth 

defects contributed to more than one 

million hospital stays in the U.S. in 

2013, resulting in $22.9 billion in 

hospital costs. Birth defects are the 

leading cause of infant mortality and the 

fifth leading cause of loss of potential 

years of life before age 65. One in five 

infant deaths is due to birth defects. 

For most birth defects, the causes are 

not known, making prevention efforts 

challenging to develop. However, to 

date, primary preventive measures are 

available for only a few birth defects. 

For example, vaccination programs have 

reduced the incidence of congenital 

rubella syndrome, Rh hemolytic disease 

of the newborn can be prevented by 

appropriate medical practices, and 

genetic counseling can provide parents 

with information about the increased 

risk of Down syndrome associated with 

advanced maternal age. Perhaps most 

importantly, folic acid intake before and 

during pregnancy can prevent many 

cases of fatal or permanently disabling 

neural tube defects such as anencephaly 

and spina bifida. 

This continued burden justifies 

reasonable attempts to reduce the 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 11443 

prevalence of birth defects. To help 

reduce birth defects among U.S. babies, 

in 1996 Congress directed the CDC to 

establish Centers of Excellence for Birth 

Defects Research and Prevention. The 

mandate was formalized with passage of 

the Birth Defects Prevention Act of 

1998. The Act amended Section 317C of 

the Public Health Service Act (42 U.S.C. 

247b–4) and authorized CDC to (1) 

collect, analyze, and make available 

data on birth defects; (2) operate 

regional centers that will conduct 

applied epidemiological research for the 

prevention of birth defects; and (3) 

provide the public with information on 

preventing birth defects. 

In response to this mandate, the 

Division of Birth Defects and Infant 

Disorders (DBDID) obtained OMB 

clearance for data collection that is 

carried out by the Centers for Birth 

Defects Research and Prevention 

(CBDRP). The CBDRP’s first research 

effort was the National Birth Defects 

Prevention Study (NBDPS), which 

began data collection in 1997 and ended 

in 2013. The CBDRPs transitioned from 

NBDPS to the Birth Defects Study To 

Evaluate Pregnancy exposures (BD– 

STEPS), which began data collection in 

2014. One of the main activities for each 

Center is to conduct BD–STEPS in their 

state. 

BD–STEPS is made up of a number of 

information collection activities. The 

interview is estimated to take 

approximately 55 minutes and is titled 

‘‘Birth Defects Prevention Study: 

Computer Assisted Telephone 

Interview.’’ For the five Centers not 

participating in the stillbirth component 

of the study, a maximum of 370 

interviews are planned per year per 

center, 270 cases and 100 controls; for 

the two Centers participating in 

additional stillbirth interviews, 590 

interviews are planned per Center, 270 

cases with birth defects, 100 controls, 

and 220 stillbirths without birth defects. 

With seven Centers and a maximum of 

3,030 interviews, the maximum 

interview burden for all Centers 

combined would be 2,778 hours per 

year. The 55-minute burden includes 

the time for the telephone consent script 

which is reviewed with the mother at 

the beginning of the call to collect the 

information via the computer assisted 

telephone interview (CATI). 

Five of the seven BD–STEPS Centers 

request consent for retrieval of leftover 

newborn bloodspots. If a maximum of 

2,590 interviews would be expected for 

seven Centers (not including interviews 

of stillbirths without birth defects), a 

maximum of 1,850 would be expected 

for five Centers requesting consent for 

retrieval of leftover newborn bloodspots 

(excluding stillbirths, for which 

newborn bloodspots are not available). 

A maximum of 15 minutes would be 

expected for the participant to read the 

bloodspot retrieval consent request and 

sign the consent form. The anticipated 

maximum burden for bloodspot consent 

would be 463 hours annually. 

With a maximum of 2,590 interviews 

planned annually (not including 

interviews of stillbirths without birth 

defects since they are not eligible for the 

online questionnaire), and 

approximately one-third of the 

respondents eligible for the online 

questionnaire (selected based on 

reporting occupations queried in the 

questionnaire), a maximum of 830 

women would receive the online 

questionnaire. Completion of the online 

questionnaire is estimated to take 20 

minutes including reading introductory 

communication. The anticipated 

maximum burden for the online 

questionnaire is 277 hours annually. 

CDC requests the release of reportable 

infectious diseases information from all 

women who complete the CATI except 

for women who experienced a stillbirth 

without a birth defect. A maximum of 

2,590 women would receive the 

infectious disease information request. 

Based on experience with consent 

forms, we expect the review, signing 

and mailing of the release of reportable 

infectious diseases information to take a 

maximum of 15 minutes for 

participants. The anticipated maximum 

burden for the reportable infectious 

diseases information is 648 hours 

annually. 

In the two Centers participating in the 

supplemental interview, mothers of 

infants with or without birth defects 

that are stillborn and controls are asked 

to participate in a supplemental 

telephone interview. The 25-minute 

supplemental interview includes the 

time for informed consent. Based on a 

maximum of 640 women to be 

interviewed with the supplemental 

questionnaire, the maximum burden 

time would be 267 hours annually. 

Although participation rates may 

vary, the total estimates of annual 

burden hours for all activities, all 

individuals, and all Centers is 4,433 

hours. There is no cost to respondents 

other than their time to participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Mother’s Interview ............................. Telephone Consent Script/BD– 

STEPS Computer Assisted Telephone Interview.

3,030 1 55/60 2,778 

Mother’s Consent for Bloodspot Retrieval.Consent for bloodspot retrieval ........ 1,850 1 15/60 463 

Mother’s Online Occupational Questionnaire.Online Occupational Questionnaire 830 1 20/60 277 

Mothers Infectious Disease Release 

Review.

Infectious Disease Request Form .... 2,590 1 15/60 648 

Mothers of AR/MA Stillbirths and 

Controls (Supplemental Telephone 

Interview).

Telephone Consent and Supplemental Interview.640 1 25/60 267 

Total ....................................... ........................................................... ........................ ........................ ........................ 4,433 


jspears on DSK121TN23PROD with NOTICES1
11444 Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–04191 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

SIP22–005, Building Resilience Against 

Climate Effects (BRACE): Enhancing 

Practical Guidance to Support Climate 

and Health Adaptation Planning. 

Date: May 4, 2022. 

Time: 11:00 a.m.–6:00 p.m., EDT. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

FOR FURTHER INFORMATION CONTACT: Jaya 

Raman, Ph.D., Scientific Review Officer, 

National Center for Chronic Disease 

Prevention and Health Promotion, CDC, 

4770 Buford Highway, Mailstop S107– 

B, Atlanta, Georgia 30341, Telephone: 

(770) 488–6511, email: JRaman@

cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–04262 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)- 

RFA–CK-22–001, Investigation of 

Monkeypox and Other Zoonotic 

Diseases in the Democratic Republic of 

the Congo (DRC); RFA–CK–22–002, 

Technological Advancement of Global 

Rabies Surveillance and Control; and 

RFA–CK–22–004, Optimization and 

Standardization of Methods to Suppress 

Ixodes scapularis and Disrupt Enzootic 

Pathogen Transmission in Settings 

Posing an Elevated Risk to Humans. 

Date: April 28, 2022. 

Time: 10:00 a.m.–5:00 p.m. (EDT). 

Place: Teleconference, Centers for 

Disease Control and Prevention, Room 

1080, 8 Corporate Square Blvd., Atlanta, 

GA 30329. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Gregory Anderson, M.S., M.P.H., 

Scientific Review Officer, National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention, CDC, 1600 Clifton 

Road NE, Mailstop US8–1, Atlanta, 

Georgia 30329, (404) 718–8833, 

ganderson@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–04261 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

PAR 20–297, NIOSH Centers of 

Excellence for Total Worker Health 

(TWH). 

Date: April 21, 2022. 

Time: 1:00 p.m.–4:00 p.m., EDT. 

Place: Video-Assisted Meeting. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Dan 

Hartley, Ed.D., Scientific Review 

Officer, Office of Extramural Programs, 

National Institute for Occupational 

Safety and Health, CDC, 1095 

Willowdale Road, Morgantown, West 


jspears on DSK121TN23PROD with NOTICES1